Molecular Partners AG Logo

Molecular Partners AG

Pioneering DARPin protein drugs for complex diseases in oncology and virology.

MOLN | SW

Overview

Corporate Details

ISIN(s):
CH0256379097 (+1 more)
LEI:
875500AXMLDAZ4D21744
Country:
Switzerland
Address:
Wagistrasse 14, 8952 Schlieren
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Molecular Partners AG is a clinical-stage biopharmaceutical company that pioneers the design and development of DARPin therapeutics, a novel class of custom-built protein drugs. The company leverages its proprietary platform to create potent and specific therapies engineered to address complex medical challenges, particularly in oncology and virology, that other drug modalities cannot readily treat. Molecular Partners develops its pipeline of innovative therapeutic candidates independently and in collaboration with global partners to deliver new treatments for patients with serious diseases.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2020-07-07 07:25
Share Issue/Capital Change
Molecular Partners AG: Molecular Partners Successfully Completes the Launch of …
English 17.3 KB
2020-04-19 23:15
Regulatory Filings
Molecular Partners Initiates Anti-COVID-19 Therapeutic Program Leveraging Multi…
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all Molecular Partners AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Molecular Partners AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Molecular Partners AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-09-09 N/A Executive member Sell None 47,784.80 CHF
2024-09-09 N/A Executive member Sell None 13,822.40 CHF
2024-04-02 N/A Executive member Sell None 243,000.00 CHF
2023-11-01 N/A Executive member Buy None 31,760.55 CHF
2022-02-15 N/A Executive member Sell None 2,410,500.00 CHF
2022-02-15 N/A Executive member Sell None 1,607,000.00 CHF

Peer Companies

CHOSA Oncology AB Logo
Develops diagnostics and targeted therapies to personalize platinum-based cancer treatments.
Sweden
CHOSA
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
CHUKYOIYAKUHIN CO.,LTD. Logo
Direct-to-home service providing medicine boxes, health products, and daily necessities.
Japan
4558
Cidara Therapeutics, Inc. Logo
Developing drug-Fc conjugates as targeted immunotherapies for cancer and serious infections.
United States of America
CDTX
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.